학제간연구 | Interdisciplinary Studies in Gambling | 跨学科研究
- date : 2015-05-20 01:10|hit : 1689
-
- Article] Utilities and disutilities for type 2 diabetes treatment-related attributes
-
DocNo of ILP: 4163
Doc. Type: Article
Title: Utilities and disutilities for type 2 diabetes treatment-related attributes
Authors: Matza, LS; Boye, KS; Yurgin, N; Brewster-Jordan, J; Mannix, S; Shorr, JM; Barber, BL
Full Name of Authors: Matza, Louis S.; Boye, Kristina S.; Yurgin, Nicole; Brewster-Jordan, Jessica; Mannix, Sally; Shorr, Jodi M.; Barber, Beth L.
Keywords by Author: type 2 diabetes; utility; disutility; standard gamble; weight change; fear of hypoglycemia
Keywords Plus: QUALITY-OF-LIFE; HEALTH STATE UTILITIES; BODY-MASS INDEX; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; INTENSIVE BLOOD-GLUCOSE; STANDARD GAMBLE; METHODOLOGICAL ISSUES; COST-EFFECTIVENESS; CLINICAL-OUTCOMES; GALLSTONE DISEASE
Abstract: Introduction Although cost-utility analyses are frequently used to estimate treatment outcomes for type 2 diabetes, utilities are not available for key medication-related attributes. The purpose of this study was to identify the utility or disutility of diabetes medication-related attributes (weight change, gastrointestinal side effects, fear of hypoglycemia) that may influence patient preference. Methods Patients with type 2 diabetes in Scotland and England completed standard gamble (SG) interviews to assess utility of hypothetical health states and their own current health state. The EQ-5D, PGWB, and Appraisal of Diabetes Symptoms were administered. Construct validity and differences among health states were examined with correlations, t-tests, and ANOVAs. Results A total of 129 patients (51 Scotland; 78 England) completed interviews. Mean utility of diabetes without complications was 0.89. Greater body weight was associated with disutility, and lower body weight with added utility (e.g., 3% higher = -0.04; 3% lower = +0.02). Gastrointestinal side effects and fear of hypoglycemia were associated with significant disutility (p < 0.001). SG utility of current health (mean = 0.87) demonstrated construct validity through correlations with patient-reported outcome measures (r = 0.08-0.31). Discussion The vignette-based approach was feasible and useful for assessing added utility or disutility of medication-related attributes.
Cate of OECD: Health sciences
Year of Publication: 2007
Business Area: gamble
Detail Business: gamble
Country: Netherlands
Study Area:
Name of Journal: QUALITY OF LIFE RESEARCH
Language: English
Country of Authors: United BioSource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA
Press Adress: Matza, LS (reprint author), United BioSource Corp, Ctr Hlth Outcomes Res, 7101 Wisconsin Ave,Suite 600, Bethesda, MD 20814 USA.
Email Address: louis.matza@unitedbiosource.com
Citaion:
Funding:
Lists of Citation: Albu J, 2003, PRIMARY CARE, V30, P465, DOI 10.1016/S0095-4543(03)00043-5; Bagust A, 2005, HEALTH ECON, V14, P217, DOI 10.1002/hec.910; BASS EB, 1994, MED DECIS MAKING, V14, P307, DOI 10.1177/0272989X9401400401; Bleichrodt H, 2003, J HEALTH ECON, V22, P1037, DOI 10.1016/S0167-6296(03)00046-8; Blonde L, 2004, CURR MED RES OPIN, V20, P565, DOI 10.1185/030079904125003278; Blumenschein K, 1998, ANN ALLERG ASTHMA IM, V80, P189; BRAZIER J, 1993, QUAL LIFE RES, V2, P169, DOI 10.1007/BF00435221; BRAZIER J, 2004, HEALTH ECON, V13, P876; BROHAN EM, 2005, ANN M INT SOC QUAL L; Brooks R, 2003, MEASUREMENT VALUATIO; CHASSANY O, 2004, PGWBI USERS MANUAL; Clarke P, 2002, MED DECIS MAKING, V22, P340, DOI 10.1177/027298902400448902; Clarke PM, 2005, DIABETOLOGIA, V48, P868, DOI 10.1007/s00125-005-1717-3; Coffey JT, 2002, DIABETES CARE, V25, P2238, DOI 10.2337/diacare.25.12.2238; Cohen JW, 1988, STAT POWER ANAL BEHA; COOK J, 1994, HEALTH ECON, V3, P157, DOI 10.1002/hec.4730030305; Costea M, 1993, Rom J Intern Med, V31, P291; SHAMOON H, 1993, NEW ENGL J MED, V329, P977; DeFronzo RA, 2005, DIABETES CARE, V28, P1092, DOI 10.2337/diacare.28.5.1092; de Galan BE, 2006, NETH J MED, V64, P269; de Grauw WJC, 2001, BRIT J GEN PRACT, V51, P527; Drummond MF, 2000, METHODS EC EVALUATIO; DUPUY HJ, 1984, ASSESSMENT QUALITY L, P173; Eddy DM, 2005, ANN INTERN MED, V143, P251; EuroQol Group, 1990, HLTH POLICY, V16, P199; Feeny D., 1991, EFFECT CANC QUALITY; FEENY DH, 1989, MED CARE, V27, pS190, DOI 10.1097/00005650-198903001-00016; Foxcroft D R, 2000, Obes Rev, V1, P121, DOI 10.1046/j.1467-789x.2000.00011.x; GAFNI A, 1994, HEALTH SERV RES, V29, P207; GARROW JS, 1985, INT J OBESITY, V9, P147; Green C, 2003, QUAL LIFE RES, V12, P565, DOI 10.1023/A:1025052609818; Groessl EJ, 2004, AM J PREV MED, V26, P126, DOI 10.1016/j.amepre.2003.10.007; Hakim Z, 2002, PHARMACOECONOMICS, V20, P393, DOI 10.2165/00019053-200220060-00004; Heine RJ, 2005, ANN INTERN MED, V143, P559; Heller S, 2004, DIABETES RES CLIN PR, V65, pS23, DOI 10.1016/j.diabres.2004.07.005; Hinz A, 2006, PSYCHOTHER PSYCH MED, V56, P42, DOI 10.1055/s-2005-867061; IRVINE AA, 1992, HEALTH PSYCHOL, V11, P135, DOI 10.1037//0278-6133.11.2.135; Jansen SJT, 1998, MED DECIS MAKING, V18, P391, DOI 10.1177/0272989X9801800406; Jia HM, 2005, J PUBLIC HEALTH, V27, P156, DOI 10.1093/pubmed/fdi025; Johnston K, 1998, SOC SCI MED, V47, P213, DOI 10.1016/S0277-9536(98)00065-3; Juniper EF, 2001, EUR RESPIR J, V18, P38, DOI 10.1183/09031936.01.00088301; Kaarlola A, 2004, INTENS CARE MED, V30, P2245, DOI 10.1007/s00134-004-2471-6; Kartman B, 2004, MED DECIS MAKING, V24, P40, DOI 10.1177/027298X03261563; Koopmanschap M, 2002, DIABETOLOGIA, V45, pS18, DOI 10.1007/s00125-002-0861-2; Krabbe P, 2003, MEASUREMENT VALUATIO; Lee AJ, 2005, DIABETIC MED, V22, P1482, DOI 10.1111/j.1464-5491.2005.01657.x; Leonardson GR, 2003, PSYCHOL REP, V93, P49, DOI 10.2466/PR0.93.5.49-58; Maddigan SL, 2003, MED DECIS MAKING, V23, P489, DOI 10.1177/0272989X03258438; Maddigan Sheri L, 2003, Health Qual Life Outcomes, V1, P78, DOI 10.1186/1477-7525-1-78; Marrero DG, 1997, DIABETES EDUCATOR, V23, P281, DOI 10.1177/014572179702300306; Marshall V, 2006, ACTA DIABETOL, V43, P6, DOI 10.1007/s00592-006-0203-9; Matza LS, 2005, QUAL LIFE RES, V14, P735; MAUSKOPF J, 2006, METHODS DESIGNS OUTC; McDowell I., 1996, MEASURING HLTH GUIDE; McEwan P, 2006, CURR MED RES OPIN, V22, P121, DOI 10.1185/030079906X80350; McQueen J, 2005, AM J HEALTH-SYST PH, V62, P2363, DOI 10.2146/ajhp050341; NICE (National Institute for Health and Clinical Excellence), 2003, GUID METH TECHN APPR; Ohsawa I, 2003, DIABETES RES CLIN PR, V62, P9, DOI 10.1016/S0168-8227(03)00145-1; Palmer AJ, 2004, CURR MED RES OPIN, V20, pS5, DOI 10.1185/030079904X1980; Purnell Jonathan Q, 2003, Treat Endocrinol, V2, P33, DOI 10.2165/00024677-200302010-00004; Redekop WK, 2002, DIABETES CARE, V25, P458, DOI 10.2337/diacare.25.3.458; Revicki DA, 1998, J AFFECT DISORDERS, V48, P25, DOI 10.1016/S0165-0327(97)00117-1; RUTTENVANMOLKEN MPMH, 1995, MED CARE, V33, P922; Scheen AJ, 2000, BIOMED PHARMACOTHER, V54, P74, DOI 10.1016/S0753-3322(00)88855-1; Secnik K, 2005, MED DECIS MAKING, V25, P56, DOI 10.1177/0272989X04273140; Stalmeier PFM, 2002, MED DECIS MAKING, V22, P53, DOI 10.1177/02729890222062919; Stavem K, 1998, EPILEPSY RES, V29, P201; Stein Ken, 2005, Appl Health Econ Health Policy, V4, P219, DOI 10.2165/00148365-200504040-00004; Sullivan SD, 2002, PHARMACOECONOMICS, V20, P1079, DOI 10.2165/00019053-200220150-00004; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Torrance G.W., 1996, QUALITY LIFE PHARMAC; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Torrance GW, 1997, AM J MANAG CARE, V3, pS8; Torrance George W, 2002, Expert Rev Pharmacoecon Outcomes Res, V2, P99, DOI 10.1586/14737167.2.2.99; U.K. Prospective Diabetes Study Group, 1999, DIABETES CARE, V22, P1125; Turner RC, 1998, LANCET, V352, P837; WARREN E, 2006, ASSESSMENT REPORT CL; Warren E, 2004, HEALTH TECHNOL ASSES, V8, P1; WEINBERGER M, 1994, MED CARE, V32, P1173, DOI 10.1097/00005650-199412000-00002; Zhou H, 2005, DIABETES CARE, V28, P2856, DOI 10.2337/diacare.28.12.2856
Number of Citaion: 80
Publication: SPRINGER
City of Publication: DORDRECHT
Address of Publication: VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
ISSN: 0962-9343
29-Character Source Abbreviation: QUAL LIFE RES
ISO Source Abbreviation: Qual. Life Res.
Volume: 16
Version: 7
Start of File: 1251
End of File: 1265
DOI: 10.1007/s11136-007-9226-0
Number of Pages: 15
Web of Science Category: Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health
Subject Category: Health Care Sciences & Services; Public, Environmental & Occupational Health
Document Delivery Number: 206TT
Unique Article Identifier: WOS:000249206500015
- reply : 0
-
- list
-
- prev
- next